Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-03-17 Regulatory Filings
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
Quebec Hospital Cuts Spine SSIs by 78%
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the RNS (Regulatory News Service) Reach platform. It details clinical study results regarding the company's product, Steriwave, and does not constitute a formal financial report, proxy, or governance document. As it is a general corporate announcement regarding operational/clinical progress that does not fit into specific categories like earnings or M&A, it is classified as a Regulatory Filing (RNS).
2025-03-17 English
Exercise of Options
Share Issue/Capital Change Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Ondine Biomedical Inc. regarding the exercise of options by a third party, resulting in the issuance of 16,666 new ordinary shares. This falls under the category of share issuance or capital changes, specifically categorized as 'Share Issue/Capital Change' (SHA).
2025-03-14 English
Grant of Options
Director's Dealing Classification · 100% confidence The document is an official announcement from Ondine Biomedical Inc. regarding the grant of stock options to two key executives (PDMRs). It includes the required FCA notification forms for transactions by persons discharging managerial responsibilities. While it involves executive compensation, the primary nature of the filing is the disclosure of director/executive dealings in company securities, which falls under the 'Director's Dealing' category.
2025-02-26 English
Seasoned MedTech Exec Appointed as CFO & COO
Board/Management Information Classification · 100% confidence The document is an official announcement from Ondine Biomedical Inc. regarding the appointment of a new Chief Financial Officer (CFO) and Chief Operating Officer (COO). This falls directly under the category of board or management changes.
2025-02-26 English
Nasal photodisinfection US market potential
Regulatory Filings Classification · 95% confidence The document is a press release distributed via the RNS Reach service. It provides an update on the company's clinical progress, specifically regarding their light-activated antimicrobial treatment and its potential for FDA approval. It does not constitute a formal financial report, proxy statement, or regulatory filing required by law, but rather serves as a corporate announcement regarding business operations and product development. As it is a general regulatory announcement that does not fit into more specific categories like earnings or M&A, it is classified as a Regulatory Filing (RNS).
2025-02-19 English
Ondine President increases shareholding
Director's Dealing Classification · 100% confidence The document is a notification of a share purchase by a person discharging managerial responsibilities (PDMR), specifically the President and CTO of Ondine Biomedical Inc. It includes the required disclosure table for such transactions, identifying the individual, the number of shares purchased, the price, and the date. This falls directly under the definition of 'Director's Dealing'.
2025-02-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.